Walleye Capital LLC Purchases 49,009 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)

Walleye Capital LLC raised its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATEFree Report) by 263.5% in the third quarter, Holdings Channel reports. The institutional investor owned 67,609 shares of the biopharmaceutical company’s stock after buying an additional 49,009 shares during the quarter. Walleye Capital LLC’s holdings in Fate Therapeutics were worth $237,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of FATE. Perceptive Advisors LLC purchased a new stake in Fate Therapeutics in the second quarter worth approximately $1,133,000. Deerfield Management Company L.P. Series C grew its stake in shares of Fate Therapeutics by 62.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 3,555,871 shares of the biopharmaceutical company’s stock worth $11,663,000 after acquiring an additional 1,365,463 shares during the last quarter. Integral Health Asset Management LLC boosted its position in shares of Fate Therapeutics by 325.0% during the second quarter. Integral Health Asset Management LLC now owns 850,000 shares of the biopharmaceutical company’s stock valued at $2,788,000 after buying an additional 650,000 shares during the last quarter. Renaissance Technologies LLC bought a new position in Fate Therapeutics in the second quarter valued at about $1,799,000. Finally, E Fund Management Co. Ltd. lifted its holdings in Fate Therapeutics by 930.2% in the second quarter. E Fund Management Co. Ltd. now owns 355,225 shares of the biopharmaceutical company’s stock valued at $1,165,000 after acquiring an additional 320,745 shares during the period. Hedge funds and other institutional investors own 97.54% of the company’s stock.

Fate Therapeutics Stock Performance

NASDAQ:FATE opened at $2.28 on Wednesday. The stock has a market capitalization of $259.67 million, a P/E ratio of -1.38 and a beta of 1.95. The company has a 50 day moving average price of $2.73 and a 200 day moving average price of $3.42. Fate Therapeutics, Inc. has a fifty-two week low of $1.96 and a fifty-two week high of $8.83.

Fate Therapeutics (NASDAQ:FATEGet Free Report) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.02. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The business had revenue of $3.07 million for the quarter, compared to the consensus estimate of $0.88 million. Research analysts forecast that Fate Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a research note on Tuesday, November 19th. HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Fate Therapeutics in a research report on Thursday, August 22nd. Bank of America upgraded Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Monday, November 18th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $5.00 price target on shares of Fate Therapeutics in a report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Fate Therapeutics currently has a consensus rating of “Hold” and an average target price of $6.75.

Check Out Our Latest Stock Analysis on FATE

Fate Therapeutics Profile

(Free Report)

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.

Featured Stories

Want to see what other hedge funds are holding FATE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fate Therapeutics, Inc. (NASDAQ:FATEFree Report).

Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.